Trial Profile
A Phase 3, Multi-centre, Randomised, Double-blind, Active-controlled, Parallel-group Trial Investigating the Efficacy and Safety of FE 999315 Following 8 Weeks of Treatment for Mild to Moderate Active Ulcerative Colitis in Japanese Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2020
Price :
$35
*
At a glance
- Drugs Budesonide (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 16 Jun 2020 Status changed from active, no longer recruiting to completed.
- 07 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 May 2020.